Novavax Inc. (NVAX)
Novavax (NVAX) Upgraded to Buy: Here's What You Should Know
Novavax (NVAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
Novavax (NVAX) reached $8.97 at the closing of the latest trading day, reflecting a +2.51% change compared to its last close.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Novavax (NVAX) Dipped More Than Broader Market Today
Novavax (NVAX) concluded the recent trading session at $8.37, signifying a -3.68% move from its prior day's close.
Here's Why Novavax (NVAX) Fell More Than Broader Market
In the latest trading session, Novavax (NVAX) closed at $9.22, marking a -6.07% move from the previous day.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax (NVAX) Stock Dips While Market Gains: Key Facts
In the latest trading session, Novavax (NVAX) closed at $9.71, marking a -1.97% move from the previous day.
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer
NVAX inks a non-exclusive Matrix-M license, securing $30M upfront, up to $500M in milestones and mid-single-digit royalties from Pfizer.
Novavax Stock Pops After Pfizer Licensing Agreement
Novavax Inc. (NASDAQ:NVAX) shares are up 3.3% to trade at $8.27 at last glance, after the vaccine company singed a licensing agreement -- worth up to $500 million, including a $30 million upfront payment -- with Pfizer (PFE) for use of its Matrix-M adjuvant for up to two disease areas.
Novavax enters license agreement with Pfizer for vaccine development
Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for infectious diseases.
Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
